IDO2 and cancer: In addition, increasing the secretion of a desired DAMP using epigenetic modulators may affect the expression of checkpoint molecules such as PD-L1 or suppressive metabolites such as indoleamine 2,3-dioxygenase (IDO1) in the cancer cells, causing them to respond to immunotherapeutic strategies differently.